Management of community-acquired pneumonia defining the role of azithromycin

Disease Management and Health Outcomes

Volumn 5, Issue 1, 1999, Pages 41-54

  Gunasekara, Nishan S ^a   Balfour, Julia A Barman ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN;

ARTICLE; BACTEREMIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; MORTALITY; NORTH AMERICA; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRACTICE GUIDELINE; TISSUE DISTRIBUTION;

EID: 0032933955     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199905010-00004     Document Type: Article

References (2)

1. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992 Nov; 44: 750-99
2. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996 Mar; 51: 483-505